aTyr Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2013
Cash & Equivalents	26.03	13.15	2.34	16.95	9.21	Upgrade
Short-Term Investments	75.62	56.17	105.58	14.74	21.93	Upgrade
Cash & Cash Equivalents	101.65	69.31	107.91	31.69	31.14	Upgrade
Cash Growth	46.66%	-35.77%	240.53%	1.75%	-37.14%	Upgrade
Receivables	2.44	11.78	0.44	2.04	0.1	Upgrade
Other Current Assets	-1.09	-0.22	5.22	1.8	0.68	Upgrade
Total Current Assets	102.99	80.87	113.57	35.53	31.93	Upgrade
Property, Plant & Equipment	14.05	11.56	1.81	2.98	4.09	Upgrade
Other Long-Term Assets	3.62	3.36	0.16	0.21	0.17	Upgrade
Total Long-Term Assets	17.66	14.92	1.97	3.2	4.26	Upgrade
Total Assets	120.65	95.79	115.54	38.73	36.19	Upgrade
Accounts Payable	3.53	3.11	1.03	1.43	0.85	Upgrade
Current Debt	1.33	0.89	0.98	0.86	9.49	Upgrade
Other Current Liabilities	11.56	9.86	4	3.57	2.58	Upgrade
Total Current Liabilities	16.42	13.86	6.01	5.86	12.92	Upgrade
Long-Term Debt	13.77	10.64	0.4	1.38	2.24	Upgrade
Total Long-Term Liabilities	13.77	10.64	0.4	1.38	2.24	Upgrade
Total Liabilities	30.18	24.5	6.41	7.24	15.16	Upgrade
Total Debt	15.1	11.53	1.38	2.24	11.73	Upgrade
Debt Growth	30.87%	737.01%	-38.45%	-80.91%	-26.82%	Upgrade
Retained Earnings	-468.02	-417.63	-372.3	-338.53	-322.3	Upgrade
Comprehensive Income	-0.07	-0.43	-0.26	-0.04	-0.04	Upgrade
Shareholders' Equity	90.66	71.46	109.3	31.65	21.19	Upgrade
Net Cash / Debt	86.56	57.78	106.53	29.45	19.41	Upgrade
Net Cash / Debt Growth	49.81%	-45.77%	261.74%	51.70%	-42.08%	Upgrade
Net Cash Per Share	1.61	2.03	5.58	3.21	5.79	Upgrade
Working Capital	86.58	67.01	107.56	29.67	19	Upgrade
Book Value Per Share	1.69	2.52	5.73	3.46	6.31	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).